Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 11 (1) , e70058
Abstract
On March 12–14, 2024, the National Institute on Aging (NIA) together with the National Institute of Neurological Disorders and Stroke (NINDS) led a workshop exploring clinically meaningful changes in the context of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) clinical trials ( https://www.nia.nih.gov/research/dbsr/workshops/clinically‐meaningful‐outcomes‐ad‐adrd‐trials ). The goals were to identify research gaps, opportunities, and tools to advance patient‐centered, equitable assessment of clinically meaningful change focused on biomarker status, cognition, and everyday function. The workshop fostered robust, multidisciplinary discussion between lived experience experts, advocates, researchers, clinicians, funders, payers, and regulators. The workshop addressed the criteria used to assess whether an intervention has had a clinically meaningful impact, including consideration of both benefit and harm. Here, we report on (1) criteria to consider for development, testing, and selection of clinically meaningful outcomes in AD/ADRD clinical trials; (2) methods to validate and customize clinically meaningful outcomes that are fit‐for‐purpose; and (3) practices that will ensure that clinically meaningful outcomes are applicable to diverse populations. Highlights: Patient‐Centered Outcomes : Inclusive AD/ADRD clinical trials incorporate assessments that reflect what matters most to those impacted by these diseases, including patient‐ and caregiver‐reported outcome measures. Culturally Relevant Assessments : There is a need for culturally sensitive and equitable assessments to better serve diverse populations in AD/ADRD research. Framework for Clinically Meaningful Change : We present a framework for defining and evaluating clinically meaningful outcomes in AD/ADRD trials, tailored to diverse stages of disease progression. Interdisciplinary Approach : We draw on insights from a multidisciplinary workshop, fostering collaboration among researchers, clinicians, and lived experience experts to advance the field.Keywords
This publication has 18 references indexed in Scilit:
- Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive StagesNeurology, 2022
- Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s diseaseAlzheimer's Research & Therapy, 2022
- 2021 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2021
- Disclosure of individual research results at federally funded Alzheimer's Disease Research CentersAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2021
- Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomesAlzheimer's Research & Therapy, 2020
- A Core Outcome Set for Nonpharmacological Community-Based Interventions for People Living With Dementia at Home: A Systematic Review of Outcome Measurement InstrumentsThe Gerontologist, 2020
- Racial disparities and temporal trends in dementia misdiagnosis risk in the United StatesAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2019
- Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrumsNature Reviews Neurology, 2018
- Impact of multiple pathologies on the threshold for clinically overt dementiaActa Neuropathologica, 2017
- Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes ScoresArchives of Neurology, 2008